التجارب السريرية بالأسفل التجارب السريرية الحالية.120 دراسات في طب الأعصاب (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. A Study to Evaluate MR of CSF Dynamics Rochester, Minn. The purpose of this study is to evaluate changes in CSF dynamics (e.g., velocity, flow rate) between patients with normal pressure hydrocephalus and healthy controls, as well as patients with other dementia disorders. A Blood Collection Protocol to Study the Immune Responses of Cancer Patients with Malignancies Rochester, Minn., Scottsdale/Phoenix, Ariz. This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies displaying one of three different patterns of antigen expression: (1) Cohort 1 focuses on cancers displaying a high (80-90%) frequency of MUC1 expression and variably high (unreported to 50%) HER2/neu (“HER2”) expression; (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated calreticulin (muCALR); (3) Cohort 3 focuses on glioblastoma multiforme (GBM) which often displays the cytomegalovirus tegument protein CMVpp65. Cohort 1 includes blood collections for in vitro studies which are a component of NIH-funded Project 3 within the Mayo Clinic Pancreatic SPORE, “Optimal Immunotargeting of MUC1 for Advanced Pancreatic Cancer” (Principal Investigator Dr. Gendler). Eligibility Criteria, keep current Eligibility Criteria, but precede by:: "Three cohorts of patients will be collected.:Cohort 1 includes (1) advanced unresectable pancreatic cancer, (2-4) advanced, unresectable breast cancer (up to 6 donors per phenotype: triple negative [HER2, estrogen and progesterone receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer, (6) advanced, unresectable ovarian cancer, (7) advanced, unresectable clear cell kidney cancer, (8) advanced, unresectable bladder cancer, (9) advanced, unresectable lung adenocarcinoma, (10) advanced, unresectable multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no clinical evidence of residual (macroscopic) disease following an attempt to perform definitive treatment (including surgery, radiation and/or adjuvant or neoadjuvant chemotherapy). Cohort 2 includes (1) muCALR+ primary MF, and (2) muCALR+ secondary MF. Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or recurrent cancers, and may undergo the collection: (1) prior to initiation of systemic therapy; (2) if patient is already engaged in an ongoing cyclical systemic therapy, collection should be within three days prior to the end of the current therapy cycle, if necessary delayed until all clinical parameters are acceptable to proceed with the next planned cycle of therapy; (3) if patient is completing non-cyclical therapy, collection should be at least 2.5-3.0 weeks after completion of the therapy, or delayed until all clinical parameters are acceptable to proceed with any planned follow-up therapy. Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a neutrophil count ≥ 1,500 /microliter, and platelets ≥ 100,000 /microliter, performed within 7 days prior to the collection. Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma Rochester, Minn. The purpose of this study is to estimate the event-free survival (EFS) distribution for newly-diagnosed patients with BRAFV600-mutant high-grade glioma (HGG) without H3 K27M mutations excluding anaplastic pleomorphic xanthoastrocytoma (aPXA) and anaplastic ganglioglioma (aGG) treated with radiation therapy followed by a maintenance combination of dabrafenib and trametinib and to compare this EFS to contemporary historical controls. In Vivo Development of Phosphorus Magnetic Resonance Imaging Technology Rochester, Minn. The goal of this study is to evaluate and optimize our existing phosphorus MRI head coil and imaging sequence on healthy human volunteers. A Study to Clarify the Relationship Between Autonomic Nervous System Regulation and Cognitive Performance Rochester, Minn. The purpose of this study is to measure changes in autonomic nervous system functioning to show the impact of down-regulation techniques under cognitive stress. Mayo Clinic Vestibular Schwannoma Quality of Life Index Assessment Rochester, Minn. The purpose of the study is to conduct cognitive testing of the recently published Mayo Clinic Vestibular Schwannoma Quality of Life (VSQOL) Index. A Study to Evaluate the Spectrum of Healthy Pediatric Inflammatory Responses to Vaccinations Rochester, Minn. The purpose of this study is to understand the role of systemic inflammation in the genesis of seizures in susceptible children by gaining a clearer understanding of the spectrum of inflammatory responses that occur in healthy children post-vaccinations. Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Subjects With SCN8A-DEE Rochester, Minn. The purpose of this study is to evaluate the long-term safety and tolerability of NBI-921352 when administered for up to 106 weeks. Also, to investigate the effect of NBI-921352 on long-term seizure control. Development of Skeletal Muscle Fibers from Patient-Derived Induced Pluripotent Stem Cells (iPSCs) Rochester, Minn. The goal of this study is to create a repository of skin fibroblasts from patients with inherited myopathies or suspected inherited myopathies. The study will optimize the development of skeletal muscle cells from patient induced pluripotent stem cells (iPSCs) and to characterize their morphological, biochemical, electrophysiological and molecular properties. The study will also use skin fibroblasts as source of DNA to investigate for research purpose the genetic defect causing the myopathy, and test in future potentially therapeutic drugs in the iPSC-derived muscle cells. Cerebral Spinal Fluid Evaluation in Individuals Who Have Idiopathic Normal Pressure Hydrocephalus (INPH) Rochester, Minn. The purpose of this study is to further characterize the serum and Cerebral Spinal Fluid (CSF) biomarker profile of idiopathic normal pressure hydrocephalus, both before and after VP shunt placement, and help differentiate this profile from Alzheimer’s disease. التصفّح دراسات سريرية السابقالصفحة السابقة توجّه للصفحة 1010 توجّه للصفحة 1111 توجّه للصفحة 1212 طلب تحديد موعد الخبرات & التصنيفاتالبحث 19/06/2024 صُنفت مايو كلينك في روتشستر بولاية مينيسوتا، ومايو كلينك في فينيكس/سكوتسديل بولاية أريزونا، ومايو كلينك في جاكسونفيل بولاية فلوريدا، ضمن أفضل مستشفيات طب الأعصاب وجراحتها في الولايات المتحدة حسب بيانات U.S. News & World Report للفترة 2024-2025. تعرف على المزيد عن هذا الشرف الأسمى طب الأعصابالصفحة الرئيسيةللقسمالأقساممُلخّصالاختبارات والإجراءاتالأمراض التي تم علاجهاالأطباءمجموعات التخصصالخبرات & التصنيفاتالتجارب السريريةالبحثتجارب Mayo Clinic وقصص المرضىالتكاليف والتأمينأخبار Mayo Clinicإحالةالمرضى الأبحاث: المرضى محور اهتمامنا إظهار النسخة النصية للفيديو الأبحاث: المرضى محور اهتمامنا [عزف موسيقي] جوزيف سيرفين، دكتور في الطب، أستاذ طب الأعصاب في مايو كلينك: تتمثّل مهمة مايو في رعاية المريض. فمصلحة المريض أولًا. ولذلك فإن مهمّتنا وأبحاثنا تهدف إلى إحراز التقدّم في طريقة الاعتناء بالمريض، وتقديم مصلحته على كل الجوانب الأخرى من الرعاية. وهذا من عدة أوجه أقرب إلى دورة متعاقبة المراحل. فالأمر يبدأ بفكرة بسيطة ثبت نجاحها في المختبر، ثم طُبِّقت على المريض في سريره، وإذا سار كل شيء على ما يرام -بمعنى أنها كانت مفيدة له- فإننا نعتمدها على أنها نهج قياسي. وهذا في رأيي واحد من السمات الفريدة التي تميّز نهج مايو كلينك في البحث -أعني التركيز على المريض- وهو يساعد بحق في تمييزه عمّا سواه. الأقسامطلب موعدمُلخّصالاختبارات والإجراءاتالأمراض التي تم علاجهاالأطباءمجموعات التخصصالخبرات & التصنيفاتالتجارب السريريةالبحثتجارب Mayo Clinic وقصص المرضىالتكاليف والتأمينأخبار Mayo Clinicإحالة المرضى ORG-20117054 الأقسام والمراكز الطبية طب الأعصاب